Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1998 Apr;62(4):842–847. doi: 10.1086/301798

A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset.

M D Lalioti 1, H S Scott 1, P Genton 1, D Grid 1, R Ouazzani 1, A M'Rabet 1, S Ibrahim 1, R Gouider 1, C Dravet 1, T Chkili 1, A Bottani 1, C Buresi 1, A Malafosse 1, S E Antonarakis 1
PMCID: PMC1377038  PMID: 9529356

Abstract

Progressive myoclonus epilepsy of the Unverricht-Lundborg type (EPM1) is a rare, autosomal recessive disorder characterized by onset at age 6-16 years, generalized seizures, incapacitating myoclonus, and variable progression to cerebellar ataxia. The gene that causes EPM1, cystatin B, encodes a cysteine proteinase inhibitor. Only a minority of EPM1 patients carry a point mutation within the transcription unit. The majority of EPM1 alleles contain large expansions of a dodecamer repeat, CCC CGC CCC GCG, located upstream of the 5' transcription start site of the cystatin B gene; normal alleles contain two or three copies of this repeat. All EPM1 alleles with an expansion were resistant to standard PCR amplification. To precisely determine the size of the repeat in affected individuals, we developed a detection protocol involving PCR amplification and subsequent hybridization with an oligonucleotide containing the repeat. The largest detected expansion was approximately 75 copies; the smallest was approximately 30 copies. We identified affected siblings with repeat expansions, of different sizes, on the same haplotype, which confirms the repeat's instability during transmissions. Expansions were observed directly; contractions were deduced by comparison of allele sizes within a family. In a sample of 28 patients, we found no correlation between age at onset of EPM1 and the size of the expanded dodecamer. This suggests that once the dodecamer repeat expands beyond a critical threshold, cystatin B expression is reduced in certain cells, with pathological consequences.

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashley C. T., Jr, Warren S. T. Trinucleotide repeat expansion and human disease. Annu Rev Genet. 1995;29:703–728. doi: 10.1146/annurev.ge.29.120195.003415. [DOI] [PubMed] [Google Scholar]
  2. Brown W. T., Houck G. E., Jr, Jeziorowska A., Levinson F. N., Ding X., Dobkin C., Zhong N., Henderson J., Brooks S. S., Jenkins E. C. Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. JAMA. 1993 Oct 6;270(13):1569–1575. [PubMed] [Google Scholar]
  3. Chong S. S., Eichler E. E., Nelson D. L., Hughes M. R. Robust amplification and ethidium-visible detection of the fragile X syndrome CGG repeat using Pfu polymerase. Am J Med Genet. 1994 Jul 15;51(4):522–526. doi: 10.1002/ajmg.1320510447. [DOI] [PubMed] [Google Scholar]
  4. Filla A., De Michele G., Cavalcanti F., Pianese L., Monticelli A., Campanella G., Cocozza S. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996 Sep;59(3):554–560. [PMC free article] [PubMed] [Google Scholar]
  5. Lafrenière R. G., Rochefort D. L., Chrétien N., Rommens J. M., Cochius J. I., Kälviäinen R., Nousiainen U., Patry G., Farrell K., Söderfeldt B. Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat Genet. 1997 Mar;15(3):298–302. doi: 10.1038/ng0397-298. [DOI] [PubMed] [Google Scholar]
  6. Lalioti M. D., Mirotsou M., Buresi C., Peitsch M. C., Rossier C., Ouazzani R., Baldy-Moulinier M., Bottani A., Malafosse A., Antonarakis S. E. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet. 1997 Feb;60(2):342–351. [PMC free article] [PubMed] [Google Scholar]
  7. Lalioti M. D., Scott H. S., Antonarakis S. E. What is expanded in progressive myoclonus epilepsy? Nat Genet. 1997 Sep;17(1):17–17. doi: 10.1038/ng0997-17. [DOI] [PubMed] [Google Scholar]
  8. Lalioti M. D., Scott H. S., Buresi C., Rossier C., Bottani A., Morris M. A., Malafosse A., Antonarakis S. E. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 1997 Apr 24;386(6627):847–851. doi: 10.1038/386847a0. [DOI] [PubMed] [Google Scholar]
  9. Lamont P. J., Davis M. B., Wood N. W. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich's ataxia in 56 patients. Clinical and genetic correlates. Brain. 1997 Apr;120(Pt 4):673–680. doi: 10.1093/brain/120.4.673. [DOI] [PubMed] [Google Scholar]
  10. Levinson G., Maddalena A., Palmer F. T., Harton G. L., Bick D. P., Howard-Peebles P. N., Black S. H., Schulman J. D. Improved sizing of fragile X CCG repeats by nested polymerase chain reaction. Am J Med Genet. 1994 Jul 15;51(4):527–534. doi: 10.1002/ajmg.1320510448. [DOI] [PubMed] [Google Scholar]
  11. Malafosse A., Lehesjoki A. E., Genton P., Labauge P., Durand G., Tassinari C. A., Dravet C., Michelucci R., de la Chapelle A. Identical genetic locus for Baltic and Mediterranean myoclonus. Lancet. 1992 May 2;339(8801):1080–1081. doi: 10.1016/0140-6736(92)90667-r. [DOI] [PubMed] [Google Scholar]
  12. Monrós E., Moltó M. D., Martínez F., Cañizares J., Blanca J., Vílchez J. J., Prieto F., de Frutos R., Palau F. Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet. 1997 Jul;61(1):101–110. doi: 10.1086/513887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Montermini L., Richter A., Morgan K., Justice C. M., Julien D., Castellotti B., Mercier J., Poirier J., Capozzoli F., Bouchard J. P. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol. 1997 May;41(5):675–682. doi: 10.1002/ana.410410518. [DOI] [PubMed] [Google Scholar]
  14. Paulson H. L., Fischbeck K. H. Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci. 1996;19:79–107. doi: 10.1146/annurev.ne.19.030196.000455. [DOI] [PubMed] [Google Scholar]
  15. Pennacchio L. A., Lehesjoki A. E., Stone N. E., Willour V. L., Virtaneva K., Miao J., D'Amato E., Ramirez L., Faham M., Koskiniemi M. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1) Science. 1996 Mar 22;271(5256):1731–1734. doi: 10.1126/science.271.5256.1731. [DOI] [PubMed] [Google Scholar]
  16. Richards R. I., Sutherland G. R. Dynamic mutations: a new class of mutations causing human disease. Cell. 1992 Sep 4;70(5):709–712. doi: 10.1016/0092-8674(92)90302-s. [DOI] [PubMed] [Google Scholar]
  17. Turk V., Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991 Jul 22;285(2):213–219. doi: 10.1016/0014-5793(91)80804-c. [DOI] [PubMed] [Google Scholar]
  18. Virtaneva K., D'Amato E., Miao J., Koskiniemi M., Norio R., Avanzini G., Franceschetti S., Michelucci R., Tassinari C. A., Omer S. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet. 1997 Apr;15(4):393–396. doi: 10.1038/ng0497-393. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES